La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Blaize Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Blaize Holdings..

Blaize Holdings (NASDAQ:BZAI) Azioni, Catena delle Opzioni

Blaize Holdings

Blaize Holdings Inc provides customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.

Barclays analyst Adam Seiden maintains MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) with a Overweight and raises the price target from $145 to $200.

News

Price Target

Analyst Ratings

Barclays Maintains Overweight on MasTec, Raises Price Target to $200

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">106.7000</td>
<td align="right">0.51</td>
<td align="right">0.48</td>
<td>21.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.0400</td>
<td align="right">0.20</td>
<td align="right">0.47</td>
<td>4.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">223.0000</td>
<td align="right">0.83</td>
<td align="right">0.37</td>
<td>4.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">90.5400</td>
<td align="right">0.32</td>
<td align="right">0.35</td>
<td>5.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">151.7600</td>
<td align="right">0.30</td>
<td align="right">0.19</td>
<td>2.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">86.1000</td>
<td align="right">0.14</td>
<td align="right">0.16</td>
<td>43.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">83.8800</td>
<td align="right">0.13</td>
<td align="right">0.15</td>
<td>14.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">132.0200</td>
<td align="right">0.18</td>
<td align="right">0.13</td>
<td>8.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">52.5701</td>
<td align="right">0.03</td>
<td align="right">0.05</td>
<td>96.0K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">260.70</td>
<td align="right">-0.19</td>
<td align="right">-0.08</td>
<td>96.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.87</td>
<td align="right">-0.02</td>
<td align="right">-0.03</td>
<td>5.6K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For July 21, 2025

Billionaire venture capitalist Chamath Palihapitiya took to X to share his thoughts on the stock market and offer some advice to investors.
What Happened: On Sunday, Palihapitiya posted about a trade idea he had shared on the All In Podcast in January.
He had suggested going long on the S&amp;P Index, tracked by SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and shorting the &#8220;Mag7,&#8221; which he referred to as the &#8220;Mean Reversion Index Trade.&#8221; This trade turned out to be a lucrative one, according to Palihapitiya.
The "Magnificent Seven" refers to a group of seven major technology giants that have had a substantial impact on both the stock market and the broader economy. This group includes Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">For those that watch the <a href="https://twitter.com/theallinpod?ref_src=twsrc%5Etfw">@theallinpod</a>, you may remember that my most obvious trade idea heading into Jan was long the S&amp;P Index and short the Mag7. Aka the "Mean Reversion Index Trade" Turned out to be free money. Very rare that the market gives you these kinds of fat pitches. <a href="https://t.co/06SheKJGLk">pic.twitter.com/06SheKJGLk</a>
&mdash; Chamath Palihapitiya (@chamath) <a href="https://twitter.com/chamath/status/1947021792943718500?ref_src=twsrc%5Etfw">July 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://benzinga.com/markets/tech/25/07/46511576/jamie-dimon-reveals-a-coffee-table-chat-with-jeff-bezos-in-1999-that-almost-made-him-never-wear-a-su" target="_blank" rel="noopener">Jamie Dimon Reveals A Coffee Table Chat With Jeff Bezos In 1999 That Almost Made Him &#8216;Never Wear A Suit Again&#8230;Live On A Houseboat&#8217;</a>
He then followed up with another post, expressing his amusement and disappointment at the number of &#8220;unsophisticated financial &#8216;investors'&#8221; commenting on the thread.
He advised these individuals to use leverage, obtain an International Swaps and Derivatives Association, be banked by a prime, and put the trade on $5-10 billion a side, stating that this is how it&#8217;s done.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">PS the number of unsophisticated financial "investors" commenting on this thread is both sad and funny. It's called leverage folks! Get an ISDA, be banked by a prime, put the trade on $5-10B a side. This is how it's done.
&mdash; Chamath Palihapitiya (@chamath) <a href="https://twitter.com/chamath/status/1947204738321203309?ref_src=twsrc%5Etfw">July 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: According <a href="https://www.forbes.com/profile/chamath-palihapitiya/">to</a> Forbes, Palihapitiya has a net worth of 1.2 billion. He is a strong advocate of SPACs, which let private companies go public with fewer regulatory hurdles. He has sponsored and invested in several SPACs, including deals with Virgin Galactic and Clover Health.
In addition to backing various emerging trends early on, Palihapitiya was an <a href="https://www.benzinga.com/crypto/25/06/45803114/if-you-invested-1000-in-bitcoin-when-chamath-palihapitiya-had-his-best-call-of-all-time-heres-how-much-youd-have-now">early advocate of</a> Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>). He revealed that he initially purchased $1 million worth of Bitcoin in 2012 based on a friend's recommendation and later increased his holdings as he gained a deeper understanding of the cryptocurrency.
He has also been unfazed by the recent decline of the U.S. dollar, indicating that he has a <a href="https://www.benzinga.com/markets/economic-data/25/07/46314576/chamath-palihapitiya-shrugs-off-dollars-11-slide-in-worst-half-century-drop-says-decay-continues-without-total-collapse">deep understanding of market trends</a> and dynamics.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://benzinga.com/news/politics/25/07/46512656/trump-says-hes-totally-revived-a-country-that-was-dead-a-year-ago-hails-his-first-6-months-back-as-" target="_blank" rel="noopener">Trump Says He&#8217;s &#8216;Revived&#8217; A Country That Was &#8216;DEAD&#8217; A Year Ago, Hails His First 6 Months Back As &#8216;Most Consequential Periods Of Any President&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock

Tech

$BTC

AAPL

AMZN

GOOG

GOOGL

MSFT

NVDA

TSLA

Chamath Palihapitiya Mocks Critics After Profiting From S&P vs Mag7 Trade: 'It's Called Leverage'

B of A Securities analyst Shaun Kelley maintains Summit Hotel Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INN#NYSE">INN</a>) with a Neutral and raises the price target from $5 to $5.75.

B of A Securities Maintains Neutral on Summit Hotel Properties, Raises Price Target to $5.75

NextNRG, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXXT#NASDAQ">NXXT</a>), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered through its Next Utility Operating System&#xAE;, smart microgrids, wireless EV charging, and mobile fuel delivery, today announced the completion of a comprehensive financial restructuring that significantly reduces the company's monthly cash burn by approximately $1 million.
The restructuring consists of two key transactions: a debt conversion agreement that converts existing debt obligations to equity at a premium to market, and a strategic refinancing that replaces high-cost short-term debt with an 8-month $2 million note. Under the debt conversion executed on July 11, 2025, NextNRG issued 1,081,395 shares of restricted common stock at $2.15 per share to an existing lender, eliminating the company's obligations to the lender. Simultaneously, the company secured new financing to pay off certain short-term debt. The shares issued cannot be sold for a minimum of six months. The net result of the two transactions was a nearly $1 million reduction to the Company's monthly burn.

Management

NXXT

NextNRG Completes Financial Restructuring, Cuts Monthly Cash Burn By $1M Through Debt Conversion And Strategic Refinancing

Barclays analyst Adam Seiden maintains Manitowoc Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTW#NYSE">MTW</a>) with a Underweight and raises the price target from $9 to $11.

Barclays Maintains Underweight on Manitowoc Co, Raises Price Target to $11

Agreement strengthens one of the world's largest co-branded portfolios, enhancing priceless experiences for AAdvantage Mastercard cardmembers
American Airlines and Mastercard today announced an extension of their decades-long partnership, reinforcing a shared commitment to delivering more rewarding travel experiences and value through advanced payments technology and services.
"American is proud to collaborate with Mastercard to deliver best-in-class travel solutions for our AAdvantage&#xAE; co-branded credit cardmembers," said American's CEO Robert Isom. "Together, we are rewarding our mutual customers with travel experiences that make their journeys truly special."
The agreement secures Mastercard as the exclusive payment network partner for American's co-branded credit cards, building on nearly 40 years of collaboration between the two companies. Together, American and Mastercard will continue to enhance the AAdvantage&#xAE; program — American's industry-leading travel rewards program — while providing cardholders with seamless and personalized experiences on every trip.

American Airlines And Mastercard Extend Exclusive Partnership To Enhance AAdvantage Co-Branded Cardholder Travel Experiences

Barclays analyst Adam Seiden maintains Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) with a Equal-Weight and raises the price target from $381 to $387.

Barclays Maintains Equal-Weight on Cummins, Raises Price Target to $387

B of A Securities analyst Shaun Kelley maintains Ryman Hospitality Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) with a Buy and raises the price target from $105 to $110.

B of A Securities Maintains Buy on Ryman Hospitality Props, Raises Price Target to $110

WIIM

GLXY

Galaxy Digital shares are trading higher after the company announced it has partnered with K Wave Media to accelerate Bitcoin treasury strategies and have access to greater institutional capital.

Connect Biopharma Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it plans to terminate the Deposit Agreement dated March 18, 2021, as amended, among the Company, Deutsche Bank Trust Company Americas (the "Depositary"), and the holders and beneficial owners of American Depositary Shares ("ADSs") evidenced by American Depositary Receipts ("ADRs") issued thereunder (the "Deposit Agreement").
The ADR program and the Deposit Agreement are expected to terminate on or about September 2, 2025. At such time, the Company's ADRs will be mandatorily cancelled and exchanged for ordinary shares at a one-for-one ratio. Immediately following the termination of the ADR program, the Company plans to list its ordinary shares on the Nasdaq Global Market ("Nasdaq") in substitution for its ADRs (the "Substitution Listing"). The Company expects that, upon the effectiveness of the Substitution Listing, its ADRs will cease to be listed on Nasdaq and the ordinary shares represented by the ADRs will commence trading on Nasdaq under the Company's existing symbol "CNTB".
The Company will instruct the Depositary to issue a termination notice to owners and holders of ADRs on or about August 18, 2025, which will provide more information regarding the termination of the ADR program.

CNTB

Connect Biopharma To Terminate ADR Program And List Ordinary Shares Directly On Nasdaq

Bernstein analyst Nikhil Devnani maintains DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Outperform and raises the price target from $210 to $265.

DASH

Bernstein Maintains Outperform on DoorDash, Raises Price Target to $265

Barclays analyst Adam Seiden maintains Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) with a Equal-Weight and raises the price target from $335 to $383.

Barclays Maintains Equal-Weight on Caterpillar, Raises Price Target to $383

B of A Securities analyst Shaun Kelley maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Buy and raises the price target from $275 to $285.

B of A Securities Maintains Buy on Hilton Worldwide Holdings, Raises Price Target to $285

Cuprina Holdings (Cayman) Limited (NASDAQ:<a href="https://www.benzinga.com/stock/CUPR#NASDAQ">CUPR</a>) ("CUPR" or "the Company"), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that Dr. Ronald A. Sherman, a leading innovator in the use of medical maggots to treat chronic wounds, has agreed to join the Company as Medical and Scientific Director in September 2025.
Cuprina also announced it has signed an agreement with Dr. Sherman licensing his 2004 FDA clearance to market Lucilia sericata Medical MaggotsTM, the first such marketing clearance in US history.&nbsp;This agreement gives Cuprina the right to manufacture, sell, use and distribute these maggots and associated dressings for use in maggot debridement therapy (MDT) in the United States.
Upon joining Cuprina, Dr. Sherman's roles and responsibilities are expected to include the following: Clinical Leadership on Bio-Therapeutics:
<ul>
<li>Serve as clinical and key opinion leader on maggot therapy, leech therapy, ichthyotherapy, and other company bio-therapeutic initiatives; and</li>
<li>Provide mentorship, insights, and scientific guidance to Cuprina and affiliated clinicians in adopting and expanding bio-therapeutic practices.</li>
</ul>
Training, Education and Awareness:
<ul>
<li>Co-develop, with Cuprina, a structured training and certification framework for bio-therapeutics;</li>
<li>Assist in designing the syllabus and modules for education and certification; and</li>
<li>Represent Cuprina as a speaker at conferences, seminars, and public events to raise awareness and advance the adoption of bio-therapeutics.</li>
</ul>
Regulatory and Clinical Trials Support:
<ul>
<li>Provide expert guidance and counsel in navigating regulatory requirements across Southeast Asia and the MENA region; and</li>
<li>Assist in designing and reviewing clinical trial protocols or supporting documentation when required by Cuprina.</li>
</ul>

Biotech

General

CUPR

Cuprina Secures Exclusive License For FDA-Cleared Medical Maggots, Appoints Dr. Ronald Sherman As Medical Director

Barclays analyst Brendan Lynch maintains Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) with a Overweight and lowers the price target from $59 to $52.

LINE

Barclays Maintains Overweight on Lineage, Lowers Price Target to $52

The positive FDA feedback allows for:
<ul>
<li>A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium subspecies paratuberculosis infected (MAP-positive) Crohn's disease (CD) patient population</li>
<li>Groundbreaking approach testing MAP as a root cause of CD, supporting RHB-204 as a potential paradigm-shifting therapy treating both the suspected cause of&nbsp;Crohn's disease and its symptoms&nbsp;</li>
<li>RedHill has initiated two new collaborations with leading academic centers utilizing cutting-edge rapid and accurate MAP detection diagnostics – the lack of which has previously been a major barrier to advancing the Company's novel anti-MAP Crohn's disease program</li>
<li>Innovative design enables a smaller sample size allowing for lower study costs and faster time to completion</li>
</ul>
Funding for this ground-breaking program expected to be non-dilutive; Grant application submitted and discussions ongoing for additional non-dilutive financing
Patent protected through 2041, orally-administered RHB-204, a next-generation optimized formulation of&nbsp;RedHill's RHB-104 designed to further enhance tolerability, safety and patient adherence, is supported by positive RHB-104[2] Phase 3 safety and efficacy results, which delivered a statistically significant 64% improvement in efficacy[3]
Expected transferal of pediatric orphan drug designation to RHB-204 as well as potential for breakthrough therapy designation, fast track designation, additional regulatory exclusivity and priority review voucher
The&nbsp;multibillion-dollar Crohn's disease market is expected to expand significantly, with sales in the key markets growing from $13.6 billion in 2024 to over $19 billion in 2033[4], presenting significant commercial potential for new, paradigm changing, FDA-approved therapies
RALEIGH,&nbsp;N.C. and TEL AVIV, Israel, July 21, 2025 /PRNewswire/ --&nbsp;RedHill Biopharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received positive feedback from the U.S. Food and Drug Administration (FDA), following a scheduled Type C meeting, in which the FDA provided guidance on the pathway to approval for the Company's potentially groundbreaking RHB-204 Crohn's disease (CD) development program.

RDHL

RedHill Biopharma Receives FDA Guidance On Approval Path For RHB-204 Crohn's Disease Program Following Type C Meeting

Dividends

UPDATE: Announced July 18, 2025, SunLink Health Systems Declares Special Cash Dividend $0.10/Share

Trump Media & Technology shares are trading higher after the company announced it has accumulated approximately $2 billion in Bitcoin and related securities.

Bernstein analyst Nikhil Devnani maintains Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Outperform and raises the price target from $55 to $60.

CART

Bernstein Maintains Outperform on Maplebear, Raises Price Target to $60

Press Releases

Blaize Partners with Turbo Federal to Procure Contracts to Accelerate AI Solutions for the U.S. Department of Defense

Blaize Announces Fiscal Year 2024 Financial Results

Blaize and BroadSat Technologies Partner to Deliver AI-Powered Video Delivery and Compute at the Edge for Global Telecom and Smart City Infrastructure

CBIST Selects Blaize to Power its 2025 Smart City Development Project

Blaize to Report First Quarter 2025 Financial Results on May 14, 2025

Blaize Announces First Quarter 2025 Financial Results

Blaize to Participate at Upcoming Ladenburg Thalmann Technology Expo

Blaize to Attend D.A. Davidson 1st Annual Consumer & Technology Conference

Blaize Secures $56M Edge AI Deployment Across Southeast Asia's Smart Infrastructure

Blaize Secures Contract to Deliver Scalable Hybrid AI Infrastructure Across Asia

BZAI

BZAIW

Alpha and Omega Semiconductor Limited - Common Shares

Alpha & Omega

CEVA

Canadian Solar

GSI Technology

Himax Technologies, Inc. - American depositary shares, each of which represents two ordinary shares.

Himax Techs

Intchains Group Limited - American Depositary Shares

Intchains Gr

ChipMOS TECHNOLOGIES INC. - American Depositary Shares

ChipMOS TECHNOLOGIES

indie Semiconductor, Inc. - Class A Common Stock

Indie Semiconductor

JinkoSolar Holding Company Limited American Depositary Shares (each representing 4 Common Shares)

JinkoSolar Holding Co

Kopin

SEALSQ

Everspin Technologies, Inc. - Common Stock

Everspin Technologies

Magnachip Semiconductor Corporation Common Stock

MagnaChip Semiconductor

MaxLinear

Nano Labs

Navitas Semiconductor Corporation - Common Stock

Navitas Semiconductor

Penguin Solutions

QuickLogic

Silicon Motion Technology Corporation - American Depositary Shares, each representing four ordinary shares

Silicon Motion Technology

SkyWater Technology

Sequans Communications S.A. American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

Blaize Holdings

Blaize Holdings (BZAI) Opzioni

Blaize Holdings (NASDAQ:BZAI) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO